search icon
      blog search icon

      PBLA Stock Is Up 33% Today: What's Driving It?

      By Fahim Awan

      Published on

      July 19, 2023

      4:25 PM UTC

      Last Updated on

      July 24, 2023

      4:19 AM UTC

      PBLA Stock Is Up 33% Today: What's Driving It?

      Panbela Therapeutics, Inc. (NASDAQ: PBLA) witnessed a surge as 33 million shares exchanged hands, propelling the stock to $2.75, up by an impressive 33.08%.

      This remarkable ascent can be attributed to a strategic divestment decision, which has fueled investor optimism and boosted PBLA’s market value today.

      Which Move Has PBLA Made?

      Panbela (PBLA) has taken significant steps to advance its position and enhance its prospects. In an important move, the clinical stage company has divested specific assets from its eflornithine pediatric neuroblastoma program.

      This strategic decision led to a collaboration with US WorldMeds (USWM), a specialty pharmaceutical company based in Kentucky. Under the agreement, Panbela stands to gain up to approximately $9.5 million in non-dilutive funding.

      In exchange for the sale of certain program assets, PBLA will receive payments as USWM achieves key milestones in clinical development, regulatory approval, and commercial sales.

      Additionally, Panbela recently secured an Issue Notification for an Australian patent that holds significant value. This patent relates to a groundbreaking process involving the production of SBP-101, a lead investigational product.

      The innovative aspect lies in reducing the synthetic steps required from seventeen to six, enabling more efficient and streamlined manufacturing. The patent, valid until 2039, was developed through a fruitful collaboration with Syngene International Ltd., an esteemed company specializing in research, development, and manufacturing services.

      Furthermore, Panbela has established an independent Data Safety Monitoring Board (DSMB) for the Phase III ASPIRE clinical trial targeting patients with untreated metastatic pancreatic ductal adenocarcinoma.

      The DSMB has successfully completed a thorough review of safety data concerning treated patients in the trial. With no identified safety concerns, the DSMB has unequivocally recommended continuing the study without any modifications.

      PBLA eagerly anticipates the interim analysis scheduled for early 2024, while concentrating on enrollment and completing site initiations.

      How PBLA Will Be Benefitting?

      These strategic moves and developments significantly benefit Panbela (PBLA) and its future prospects. The recent patent issuance reinforces PBLA’s position and bolsters its patent portfolio, thereby providing robust support for its clinical programs.

      Importantly, the patented process utilizes a more readily available pharmaceutical starting material, ensuring enhanced availability of the drug supply going forward.

      Panbela is poised to leverage these advancements and propel itself forward as a frontrunner in the field of disruptive therapeutics.

      More From Stocks telegraph